Navigation Links
Less education may lead to delayed awareness of Alzheimer's onset
Date:1/23/2008

Jan. 23, 2008 -- A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.

Scientists at the Alzheimer's Disease Research Center (ADRC) at Washington University School of Medicine in St. Louis reviewed data on 1,449 Alzheimer's patients from their center and 21,880 patients from the National Alzheimer's Coordinating Center (NACC), a collaboration of approximately 30 Alzheimer's disease research centers nationwide.

"We may have a group of people who are at risk for slightly delayed detection of Alzheimer's disease," says lead author Catherine Roe, Ph.D., a neurology research instructor at the ADRC. "Early detection of Alzheimer's disease is important as we progress toward treatments and cures because those treatments will need to be applied as early as possible to have the maximum possible benefit."

The paper appears in this month's issue of Archives of Neurology.

In an earlier study of patients with a form of Alzheimer's disease linked to a genetic mutation, Roe and other Washington University researchers found patients with more years of education were likely to be diagnosed with Alzheimer's disease earlier. This surprised them because higher levels of education have typically been associated with decreased risk of Alzheimer's disease.

The new study confirmed those surprising results, revealing that patients with 12 years or more of schooling were on average slightly younger when diagnosed with Alzheimer's disease than patients with less than eight years of schooling. Age of diagnosis for a group with eight to 11 years of schooling fell in-between the other two groups.

Next, researchers analyzed the severity of patients' dementia when they went to the Alzheimer's disease center for the first time. They found that
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines
2. The First Annual LOVE L.A. Show Promotes Sensuality, Relationships and Sexual Education
3. First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid
4. Heart patients find education programs lead to better health
5. International Development Expert to Lead the Pan American Health and Education Foundation
6. 2007: A Watershed Year for Lupus Research and Education
7. DATATRAK International Launches Innovative, Interactive Educational Webcast Series
8. New Survey Underscores Importance of Psychosocial and Educational Needs Among Women with Advanced Breast Cancer
9. Survey underscores importance of emotional/educational needs among women with advanced breast cancer
10. TriWest Contributes $25,000 to Washington National Guard Fund and Sponsors Education for Teachers of Military Children
11. Survey points out need for education for primary care physicians on rarely seen cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 1Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 1CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 3Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 1Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 2